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Abstract
Background: The Six1 homeobox gene is highly expressed in the embryonic mammary gland, continues to be
expressed in early postnatal mammary development, but is lost when the mammary gland differentiates during
pregnancy. However, Six1 is re-expressed in breast cancers, suggesting that its re-instatement in the adult
mammary gland may contribute to breast tumorigenesis via initiating a developmental process out of context.
Indeed, recent studies demonstrate that Six1 overexpression in the adult mouse mammary gland is sufficient for
initiating invasive carcinomas, and that its overexpression in xenograft models of mammary cancer leads to
metastasis. These data demonstrate that Six1 is causally involved in both breast tumorigenesis and metastasis, thus
raising the possibility that it may be a viable therapeutic target. However, because Six1 is highly expressed in the
developing mammary gland, and because it has been implicated in the expansion of mammary stem cells,
targeting Six1 as an anti-cancer therapy may have unwanted side effects in the breast.
Results: We sought to determine the role of Six1 in mammary development using two independent mouse
models. To study the effect of Six1 loss in early mammary development when Six1 is normally expressed, Six1
-/-
embryonic mammary glands were transplanted into Rag1
-/- mice. In addition, to determine whether Six1
downregulation is required during later stages of development to allow for proper differentiation, we
overexpressed Six1 during adulthood using an inducible, mammary-specific transgenic mouse model.
Morphogenesis of the mammary gland occurred normally in animals transplanted with Six1
-/- embryonic mammary
glands, likely through the redundant functions of other Six family members such as Six2 and Six4, whose
expression was increased in response to Six1 loss. Surprisingly, inappropriate expression of Six1 in the adult
mammary gland, when levels are normally low to absent, did not inhibit normal mammary differentiation during
pregnancy or lactation.
Conclusions: Six1 is not critical for normal mammary gland development, since neither loss nor inappropriate
overexpression of Six1 adversely affects normal mammary gland development or function. However, as both Six2
and Six4 levels are increased in Six1
-/- mammary glands, we postulate that these Six family members are
functionally redundant in the gland, as is true of many homeobox gene families. This data, in conjunction with
recent findings that Six1 is capable of promoting breast cancer initiation and progression, suggest that Six1 may
serve as a reasonable chemotherapeutic target in a clinical setting, particularly for those women diagnosed with
breast cancer in their childbearing years.
Background
Homeodomain-containing transcription factors are
“master regulators” of normal development, controlling
important cellular mechanisms, such as proliferation,
differentiation, apoptosis, cell shape, cell adhesion and
migration [1]. In addition to their important roles in
normal development, numerous homeobox genes are
misexpressed in both solid tumors [2,3] and hemato-
poietic malignancies [4], where it is thought that they
impact neoplastic disease by reinitiating their develop-
mental programs [1].
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tant developmental regulators that are frequently misex-
pressed in cancers [5]. In the majority of cases studied,
members of the Six family promote expansion of pro-
genitor cell populations prior to differentiation, primarily
through pro-proliferative and pro-survival mechanisms
[6-9]. The most extensively studied Six family member in
cancer is Six1, which regulates proliferation, survival,
migration and invasion in both a developmental and
tumorigenic context [10-13]. Six1 is broadly expressed in
the developing embryo, in organs such as the kidney
[14-16], muscle [15-17], sensory structures [14,18-20],
and craniofacial structures arising from Rathke’sp o u c h ,
including the pituitary, thyroid, and parathyroid glands,
head muscles, facial skeleton, salivary glands, and cranial
nerves [14,21]. Given the broad expression pattern of
Six1 during embryogenesis, it is no surprise that its loss
results in a variety of profound defects. For example, the
Six1 knockout mouse dies shortly after birth due to
hypoplasia of the diaphragm skeletal muscle, which inhi-
bits its ability to breathe [17]. In addition to muscle
hypoplasia and thoracic skeletal defects that are found
throughout the Six1 knockout mouse [17], defects in
other organs are observed, including the kidney, thymus,
and craniofacial structuress u c ha st h ei n n e r ,o u t e ra n d
middle ear, the olfactory epithelium, the craniofacial ske-
leton, and the lacrimal and salivary glands
[8,14-17,19,22]. Interestingly, the majority of Six1 knock-
out defects are due to a reduction in proliferation and an
increase in apoptosis, resulting in the reduction in size or
the complete loss of an affected organ. However, Six1
may play additional roles during development, since Six1
knockout mice display significant defects in the differen-
tiation of epibranchial progenitor cells into sensory gang-
lia [19], and since loss of Six1 in combination with loss of
Six4 leads to defects in muscle cell differentiation and
migration [23].
While expression of Six1 is low or absent in most
adult tissues [11], it is re-expressed in a number of dif-
ferent human cancers including cervical [24], hepatocel-
lular [25], ovarian [10], and breast cancer [11,26,27], as
well as in alveolar rhabdomyosarcomas (RMS) [12,28],
and Wilms’ tumors [29]. Six1 has been extensively stu-
died in breast cancer, where it is overexpressed in 50%
of primary breast cancers, and 90% of metastatic lesions.
These data suggest that Six1 may play an important role
not only in the early stages of breast cancer, but also in
the progression of breast cancer [11,27]. We recently
demonstrated that Six1 overexpression in the mouse
mammary gland is sufficient to induce tumorigenesis,
leading to highly aggressive and invasive mammary
tumors, many of which undergo an epithelial to
mesenchymal transition (EMT) [30]. Interestingly, EMT
has recently been associated with stem cell
characteristics, and indeed we found that Six1 overex-
pression in mammary epithelial cells led not only to
tumor formation, but also to an expansion of mammary
stem/progenitor cells. In addition, we have recently
shown that Six1 overexpression can induce metastasis in
a xenograft model of breast cancer [31]. Since Six1
expression is often increased in cancers derived from
tissues where it plays an important developmental role,
including kidney and muscle [28,32], and since Six1 can
increase the mammary stem/progenitor pool [30], we
sought to determine if it is involved in the normal
development of the mammary gland. In the present
study, we have analyzed the expression pattern of Six1
during mammary gland development, and have explored
the biological role of both inactivation and overexpres-
sion of Six1 in the development and function of the
mouse mammary gland.
Methods
Experimental Animals
Mice were housed at the Center for Comparative Medi-
cine at the University of Colorado Denver (UCD)
Anschutz Medical Campus and treated in accordance
w i t ht h eN I HG u i d et oH u m a n eU s eo fA n i m a l si n
Research. All animal protocols were approved by the
UCD-Institutional Animal Care and Use Committee
(IACUC). Six1-deficient mice were previously described
[16]. Two breeding pairs of heterozygous mice were
used to initiate and maintain a breeding colony. Geno-
typing was performed using PCR with the following pri-
mer sets: the wild type allele was detected with
WTmSix1F5 ’ GCG CCC GGG CCC GTG CGC CCC 3’
(sense) and WTmSix1R5 ’ GCT TTC AGC CAC AGC
TGC TGC 3’ (antisense), and the mutated allele was
detected with WTmSix1Fa n dK O Six1R5 ’ TGC CCC
AGG ATG TTG CCG TCC 3’ (antisense). The embryos
used in transplant experiments were first identified via
phenotypic differences and EGFP expression of the
whole embryo, after which PCR was used to confirm the
genotype. C57Bl6/J mice were used for northern blot
analysis and the developmental stages examined were
E17.5, neonate (1 day post-partum), 5 and 10 week vir-
gin, pregnancy (early: 5 days, middle: 12 days, late: 17
days), day 4 of lactation, and day 4 of involution. For
embryonic and neonatal stages, each sample represents
a pool of at least 15 animals. For all other stages, each
sample represents a pool of 3 animals. For pregnancy,
lactation, and involution, 10-week old mice were used
and for involution studies, mice were allowed to lactate
for 5 days prior to pup removal. qRT-PCR analysis was
performed using Six1 knockout, heterozygote, and wild-
type animals consisting of mammary glands harvested
from 5 mice at embryonic day 18.5, representing a total
of 15 animals for each genotype.
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background strain (obtained from L Chodosh) [33] were
intercrossed with hemizygous TetSix animals to obtain
the following genotypes: wild type, MTB, TetSix, and
TOSix (bi-transgenic animals) as previously described
[30]. Female littermates from the MTB and TOSix gen-
otypes (6239 and 4922 lines) were mated and began
treatment with water containing 5% sucrose and 2 mg/
ml doxycyline (Sigma) at 12 weeks of age. A subset of
TOSix animals were mated and treated with water con-
taining 2% sucrose as a vehicle control as described
[30]. Water was light-protected and changed weekly.
Animals were sacrificed at pregnancy day 18 (P18) of
first pregnancy for pregnancy timepoint and expression
studies (qRT-PCR) and at lactation day 2 (L2) of first
pregnancy for lactation timepoint. Animals were sub-
jected to three rounds of pregnancy and were weaned of
last litter at least four weeks before sacrificing to deter-
mine the state of regression of the mammary gland.
Animals used for pup weight experiments were also
subjected to three rounds of pregnancy. Litter sizes were
normalized to eight pups, including any necessary fos-
tering, and weights were taken each day from L1 to L21
during one of the three pregnancies, selected at random.
Data were plotted based on average weight per pup and
error bars reflect ± standard error of the mean (sem).
Lactation and mammary regression experiments were
only performed using dox-treated MTB and TOSix
animals.
RNA Isolation
For embryonic and neonatal stages, all mammary glands
were taken and pooled as one sample. For later stages,
the fourth mammary gland of female mice was used.
Samples were flash-frozen in liquid nitrogen, and stored
at -80°C. Total cellular RNA was isolated using Trizol™
reagent (Invitrogen) per manufacturer’sp r o t o c o l .T h e
concentration and purity of RNA in each sample was
determined by analyzing spectrophotometric absorption
at 260/280 nm (Beckman).
Northern Blot, qRT-PCR, and RT-PCR
Northern blotting was performed as described using
probes made against full-length mouse Six1 and mouse
b-actin [11]. For each timepoint, 20 μgo ft o t a lR N A
were electrophoresed in a formaldehyde-containing gel.
The blot was stripped between hybridizations.
All RNA samples used for qRT-PCR analysis were iso-
lated using the RNeasy Micro Kit (Qiagen), and were
treated with DNase I in order to eliminate genomic
DNA contamination. Two micrograms of total RNA per
sample were used to generate cDNA using iScript per
manufacturer’s protocol (Bio-Rad). qRT-PCR for the
HASix1 transgene was performed as previously
described using TaqMan fluorescence probes [30]. qRT-
PCR for mouse Six family members was performed
using a model CFX96 instrument (Bio-Rad). Amplicons
were detected using TaqMan fluorescence probes per
manufacturer’s protocol (IDT Integrated DNA Technol-
ogies). The primers and probes used for this study were
as follows: mSix1 5’ AAA GGG AGA ACA CCG AAA
AC 3’ (sense), 5’ GGG GGT GAG AAC TCC TCT TC
3’ (antisense), and 5’ ACT CCT CCT CCA ACA AGC
A G AA T CA3 ’ (probe), mSix2 GCC AAG GAA AGG
GAG AAC AGC 3’ (sense), 5’ GCG TCT TCT CAT
CCT CGG AAC 3’ (antisense), and 5’ ACC GAC TTG
C C AC T GC C AT T GA G CG3 ’ (probe), mSix4 5’ACG
TCC GAG ACC CAG TCC AAA AG 3’ (sense), 5’ TAT
CTT AGC ATT TCC AAT TTG TTG C 3’ (antisense),
and 5’ CCA GTA CCG AGG ATG AAT CCA GCA A
3’ (probe), and mSix5 5’ CCT AGT GAA TGG GAG
CTT CCT G 3’ (sense), 5’ CCT TGG AGA CTG GGC
TGT G 3’ (antisense), and 5’ CCA GCA GTG CTC
CTC AAT GGT AGC C 3’ (probe). Target genes were
analyzed using standard curves to determine relative
levels of gene expression, and individual cDNA samples
were normalized according to the levels of cytokeratin14
(a marker of epithelial cells) using the following primers
and probe: 5’ GAG GAC TTG GTA GTG GAT TTG G
3’ (sense), 5’ AGC CCA TCA CCA ATA CCA C 3’
(antisense), and 5’ AAG ACC ACC ACC AAG ACC
ACC ACC A 3’ (probe). Analysis was performed using
CFX manager version 1.0 (Bio-Rad). Statistics were gen-
erated using Prism 4 software (GraphPad) and p values
determined using paired, 2-tailed student’s t-Test. Error
bars represent average ± SEM.
Before performing the RT-PCR reactions used to
assess the expression of Six1 in knockout mice, all RNA
samples were treated with DNase I (amplification grade,
Invitrogen) for 10 min at room temperature in order to
eliminate genomic DNA contamination. Two micro-
grams of total RNA per sample were used to generate
cDNAs using Superscript II RNase H-reverse transcrip-
tase (Invitrogen). The resulting cDNAs were subse-
quently amplified in a 50 μl reaction mixture containing
1 μM of each primer, 2 mM MgCl2,0 . 8m Md N T P s
and 0.025 U/μl Taq DNA polymerase. Actin was used
as a housekeeping control. Primer pairs used to amplify
mouse Six1 (WT allele) were 5’ GAA TCA ACT CTC
TCC TCT GG 3’ (sense) and 5’ TTA GGA ACC CAA
GTC CAC CA 3’ (antisense), for EGFP (mutated allele)
5’ CTG GTG ACC ACC CTG ACC TAC 3’ (sense) and
5’ TGA TCC CGG CGG CGG TCA CGA A 3’ (anti-
sense), and for actin 5’ TAT CCT GAC CCT GAA
GTA CC 3’ (sense) and 5’ G G TC A GG A TC T TC A T
GAG GT3’ (antisense). After denaturation for 2 min at
94°C, 30 cycles of amplification were performed using a
thermocycler, followed by a final extension of 10 min at
72°C. The cycling parameters were: denaturation for 30
sec at 94°C, annealing for 1 min at 55°C, extension for 2
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were electrophoresed on a 1% agarose gel containing 0.5
μg/ml of ethidium bromide.
Histology and Immunofluorescence
Mammary glands were fixed in 4% paraformaldehyde
overnight at 4°C, processed on a standard histology pro-
cessor, embedded in paraffin, and cut into 3-5 micron
sections. For histologic analysis, sections were stained
with hematoxylin and eosin (H&E). For immunofluores-
cence, after dewaxing and hydration in graded alcohol
solutions, the sections were treated with 10 mM citric
acid, pH 6.0, in a microwave for 20 min, divided into 2
cycles. To prevent non-specific binding, the tissues were
blocked with the M.O.M. mouse Ig blocking reagent
(Vector Laboratories) in PBS for 16 h at 4°C. The tissues
were then incubated with monoclonal mouse anti-GFP
antibodies (Chemicon International), washed with PBS,
and incubated with goat anti-mouse IgG conjugated
with fluorescein (Calbiochem). Tissues untreated with
primary antibodies were used as negative controls.
Mammary Gland Transplantation
Whole mammary gland transplants were performed as
described [34]. Briefly, pregnant female mice heterozy-
gous for deletions in the Six1 gene were mated to het-
erozygous males and sacrificed at day 18 of pregnancy,
at which time pups were removed. Animals were intra-
peritoneally injected with 100 mg/kg of BrdU two hours
prior to euthanizing. Embryonic mammary glands from
Six1
+/+ and Six1
-/- embryos were dissected with the aid
of a stereoscopic microscope, and transplanted between
the skin and abdominal wall (their normal position) of
5-week old C57Bl6/J-Rag1
-/- mice (Jackson Labora-
tories). The mammary glands were allowed to develop
for 5 and 10 weeks. In some cases, mice were mated 10
weeks post-transplantation and the mammary tissues
were harvested during pregnancy (5, 12 and 17 days).
For each time-point, 3-5 transplant procedures per gen-
otype were performed. The tissues were removed, fixed
in 70% ethanol, embedded in paraffin, sectioned at
5-μm, and hematoxylin/eosin (H&E) stained.
Cell Proliferation and Cell Death Assays
Cell proliferation was measured via BrdU incorporation
using an immunohistochemical analysis kit (Amersham),
whereas cell death assays were performed by terminal
deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL) analysis using an apoptosis detection
kit (Intergen).
Results
Six1 is dynamically expressed in the epithelium of the
developing mammary gland
To examine whether Six1 is dynamically expressed in
the developing mammary gland, therefore suggesting a
functional role for the gene in this organ, we evaluated
its expression by northern blot analysis using RNA iso-
lated from mouse mammary glands encompassing dif-
ferent developmental stages. Six1 transcript levels were
highest in embryonic day 17.5 (E17.5) embryos, and
decreased progressively until day 5 of pregnancy, after
which levels remained low during late pregnancy, lacta-
tion, and involution (Fig. 1A). This data confirms pre-
viously published qRT-PCR data [26].
While qRT-PCR and Northern blot data are suggestive
of a dynamic pattern of Six1 expression in the mam-
mary gland, they do not assess the cell type(s) in the
mammary gland in which Six1 is expressed. Thus, to
determine the spatial expression pattern of Six1 in the
mammary gland, we utilized the previously described
Six1 knockout mouse model [16]. Immunofluorescence
analysis was performed on mammary glands isolated
from Six1 heterozygote females, in which enhanced
green fluorescent protein (EGFP) had been knocked into
the Six1 locus [16]. Strong EGFP expression was
observed in the invaginating epithelium in the mammary
bud and in the developing muscle at day E17.5 (Fig. 1B).
In addition, EGFP was detected in the ductal epithelial
cells of the pubertal mammary gland (Fig. 1B). There-
after, EGFP expression diminished in early pregnancy
and reached a marginal level from mid-pregnancy
through involution (data not shown). These data
demonstrate that Six1 is expressed in the epithelial com-
partment of the mammary gland early during mammary
development.
Six1 expression is increased in cancers derived from
tissues where it plays an important developmental role,
including Wilms’ tumors (derived from the kidney) and
rhabdomyosarcoma (derived from the muscle)
[12,28,29]. Six1 is also overexpressed in breast cancers
[11,27], and it has recently been shown to initiate inva-
sive and aggressive mammary tumorigenesis and metas-
tasis in both transgenic and xenograft mouse models
[30,31]. Thus, we sought to determine whether Six1
plays a role in normal mammary gland development
using the previously described Six1 knockout mouse
model [16].
Loss of Six1 expression does not affect mammary gland
morphogenesis
Embryonic development of the mammary gland begins
at day 12 with an invagination of the epidermis that
results in a bulb-shaped assembly of epithelial cells,
referred to as the mammary bud, surrounded by a layer
of specialized mesenchymal cells. Around day 16, the
mammary bud begins to elongate and to penetrate into
the mesenchymal layer, initiating ductal branching mor-
phogenesis [35]. Because Six1 is dynamically expressed
throughout mammary gland development, and because
of its recently described role in the expansion of mam-
mary stem/progenitor cells [30], we reasoned that Six1
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d e v e l o p m e n tt h a tr e s u l ti nt h eo u t g r o w t ho fad u c t a l
tree from the embryonic mammary bud.
To examine whether Six1 is indeed important for this
early mammary gland expansion, we first analyzed
glands from Six1
-/- embryos at days 15.5 and 18.5 of
embryogenesis. To confirm the genotype of the mice
used in this study, PCR analysis of tail DNA was per-
formed using specific primer pairs to detect both the
wild type and mutated alleles (Fig. S1A in Additional
File 1). Expression of Six1 was examined in wild type,
heterozygote and knockout mouse mammary glands by
RT-PCR (Fig. S1B in Additional File 1), confirming the
absence of Six1 in the mammary gland of the Six1
knockout mouse. E15.5 and E18.5 mammary glands
from Six1
-/- mice showed completely normal morpho-
genesis compared with litter-matched wild type mice
(data not shown). Six1
-/- embryonic mammary glands
were smaller than Six1
+/+ mammary glands; however,
Six1
-/- embryos were also smaller than litter-matched
Six1
+/+ embryos. Thus it is not clear whether the reduc-
tion in size is intrinsic to the mammary bud itself.
Although no abnormalitiesw e r ef o u n di nt h em a m -
mary bud, we further sought to determine if disruption
of the Six1 gene resulted in developmental defects in
the mammary gland after embryogenesis; particularly
since Six1 is still highly expressed in the neonatal and
pubertal mammary gland, with more modest expres-
sion observed in the virgin adult and early pregnant
mammary gland. Because Six1
-/- mice die shortly after
birth, it was necessary to graft the E18.5 whole mam-
mary gland into Rag1
-/- mice. The rate of successful
mammary grafts was ~75%, independent of the geno-
type of the gland. Transplanted mammary glands from
b o t hw i l dt y p ea n dk n o c k o u tm i c ef o r m e dan o r m a l
branched ductal network at 5 and 10 weeks post-trans-
plant (Fig. 2A, B, C, and 2D). Recipient mice were
then mated to induce the differentiation of the mam-
mary gland that occurs in pregnancy. Six1
+/+ glands
are shown during early (Fig. 2E), middle (Fig. 2G), and
late (Fig. 2I) pregnancy. Development of ducts and
alveoli in Six1
-/- glands are normal (Fig. 2F, H, and 2J),
as compared to Six1
+/+ glands. Alveoli in late pregnant
glands from Six1
-/-and Six1
+/+ animals were equivalent
in size and a high proportion of their epithelial cells
contained large cytoplasmic lipid droplets, indicating
that secretory differentiation is also unaffected by Six1
d e f i c i e n c y[ 3 6 ] .T h u s ,s u r p r i s i n g l y ,n os t r i k i n gp h e n o -
type in mammary gland development was observed in
the absence of Six1.
Since Six1 is known to control both cell proliferation
and survival [7,8,15,16,26], we sought to determine if a
deficiency in Six1 could subtly alter either mechanism
by examining BrdU incorporation and TUNEL analysis,
respectively, in wild type, and knockout mammary
glands. BrdU- and TUNEL-positive cells were counted
separately in the ductal and alveolar cells. There was no
statistical difference between the number of BrdU-
positive cells in Six1
-/- alveolar and ductal cells com-
pared to Six1
+/+ cells (Fig. S2 in Additional File 2).
Figure 1 Six1 is dynamically expressed during mouse mammary gland development. (A) Total RNA was isolated from different stages of
mammary gland development and analyzed by northern blot. Note that Six1 is expressed at high levels until the fifth day of pregnancy when
its level drops off significantly. (B) Mammary glands from Six1 heterozygote females were collected, fixed, and serial sections were stained with
hematoxylin and eosin (H&E) or immunostained for EGFP, which replaced one allele of Six1. Arrows point to an island of mammary epithelial
cells in the E17.5 embryo, which show intense positive staining for EGFP. Arrowheads point to developing muscles that are also EGFP-positive.
Magnification, e17.5: ×40; 5 Weeks Virgin: ×100.
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-/- mice show that Six1 is not necessary for the normal
development of the mammary gland. Developmental stages are shown on the left, and the genotype of the animal from which the glands
are derived is shown at the top. (A-B) At 5 weeks post-transplant, Six1
+/+ and Six1
-/- mammary glands were composed of epithelial ducts
embedded in a soft connective tissue rich in fat. (C) A view of a Six1
+/+ mammary gland 10 weeks post-transplant shows a normal appearance.
(D) The Six1
-/- mammary gland 10 weeks post-transplant demonstrates that the mammary ductal network is unaffected in the absence of Six1.
Ten weeks after the transplant procedure, Rag1
-/- mice were mated and the transplanted mammary glands were analyzed at day 5 (E and F), day
12 (G and H) and day 17 (I and J) of pregnancy. Alveologenesis in pregnancy was not affected by Six1 deficiency.
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tive cells was observed between Six1
+/+ and Six1
-/-
transplants (data not shown). These results indicate that
the absence of Six1 does not compromise mammary
gland development on a gross level, and that prolifera-
tion and apoptosis are also not significantly affected by
its absence.
Six2 and Six4 transcript levels are elevated in Six1
-/-
mammary glands
Several studies suggest that a compensatory mechanism
exists amongst Six family members. Such studies include
knockout mouse analyses that demonstrate that Six1 can
compensate for Six4, since the Six1/Six4 double knock-
out animals have more profound phenotypes than do
the Six1 or Six4 single knockout animals [23,37]. Addi-
tionally Six2, the family member most closely related to
Six1, has been implicated in promoting a stem/
progenitor phenotype in the kidney [38], suggesting that
it may have similar functions to Six1, albeit in a differ-
ent organ system. To determine if other Six family
members may functionally compensate for the loss of
Six1 in the mammary gland, we performed qRT-PCR
analysis for all 6 Six family members in wild-type, het-
erozygous, and knockout genotypes, using mammary
glands harvested at E18.5. Of the 6 Six family members,
four were expressed in the E18.5 wild type mammary
glands, including Six1, Six2, Six4,a n dSix5 (Fig. 3A, B,
C, and 3D), whereas Six3 and Six6 did not amplify at
detectable levels in any of the genotypes (data not
shown). As expected, Six1 levels were reduced to about
half of wild type levels in the Six1 heterozygote mam-
mary glands, and were completely absent in the Six1
-/-
mammary glands (Fig. 3A). In contrast, Six5 levels
remained constant in all genotypes (Fig. 3D).
Figure 3 Six1-related family members Six2 and Six4 are upregulated in Six1
-/- mammary glands. (A) qRT-PCR analysis confirms that Six1
transcript is not present in Six1
-/-mammary glands. (B) Six2 and (C) Six4 RNA is elevated in Six1
-/- mammary glands. (D) Six5 transcript levels are
not significantly different in Six1
-/- mammary glands as compared to wild-type controls. Data (A-D) was obtained from three pooled samples for
each genotype, consisting of mammary glands harvested from 5 mice at embryonic day 18.5, representing a total of 15 animals for each
genotype. Graphs are representative of two independent experiments. Error bars denote mean ± sem. P-values were obtained using a paired 2-
tailed student’s t-Test.
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elevated in a statistically significant manner in Six1
-/-
mammary glands (Fig. 3B and 3C). Together, these data
suggest that other Six family members may compensate
for the loss of Six1 function, particularly Six2 and Six4.
Six1 overexpression in the mammary gland during
pregnancy does not impair normal development
Although the results from our knockout studies sug-
gested that Six1 is not required for mammary gland
development, we hypothesized that maintenance of Six1
expression during pregnancy, lactation, and involution,
when Six1 is normally downregulated, may inhibit dif-
ferentiation of the gland. To test this hypothesis, we uti-
lized a previously described inducible mouse model to
overexpress Six1 specifically in the adult mammary
gland [30]. Briefly, we crossed the MTB transgenic line
expressing an MMTV-LTR driven reverse tetracycline
transcriptional activator (rtTA)[ 3 9 ]w i t ht r a n s g e n i c
mice containing Six1 downstream of tet operator
sequences (TetSix line), resulting in bi-transgenic off-
spring (TOSix). When the bi-transgenic animals are
treated with water containing doxycycline (dox), rtTA is
activated and able to bind to the tet-promoter, initiating
transcription of Six1. Two transgenic lines, 4922 and
6239, were fully characterized [30] and chosen for the
further experimentation.
qRT-PCR data has shown that the Six1 transgene is
expressed in aged, uninduced TOSix animals at low levels
[30], demonstrating that the expression of Six1 is not
completely dependent on dox induction in aged animals.
Interestingly, tumor formation occurs at a higher fre-
quency in the animals that express low levels of Six1,
indicating that Six1 may act in a dose-dependent manner
to induce mammary tumors [30]. Therefore, we sought
to determine if Six1 is expressed in younger, uninduced
TOSix animals, the focus of our mammary developmen-
tal studies, and whether Six1 was tightly controlled by
dox in these animals. Twelve week old TOSix and MTB
females were mated to wild-type males, and concurrently
began continuous treatment with water containing 2 mg/
ml dox or with sucrose as a vehicle control. At P18,
females were sacrificed and their mammary glands
excised for analysis. qRT-PCR data demonstrates that the
Six1 transgene is expressed at low levels in the unin-
duced, sucrose-treated animals (-dox), but at much
higher levels in the induced animals (+dox) (Fig. 4A).
Thus, as was observed in the aged population, low levels
of Six1 transgene expression can be observed in the
mammary glands in the absence of dox induction. There-
fore, we included animals from both cohorts in a number
of the following studies to determine if the dose of Six1
has any affect on normal mammary development.
Hematoxylin and eosin (H&E) stained sections reveal
that mammary glands taken from TOSix sucrose-
treated or dox-treated animals display normal histology
during pregnancy, and contain expanded alveoli that
are producing lipid droplets, resembling the MTB con-
trol mammary glands (Fig. 4B and 4C). These data
indicate that inappropriate Six1 expression, at either
low or high levels, did not impact differentiation dur-
ing pregnancy.
Lactation and milk production occur normally in
mammary glands overexpressing Six1
To determine if Six1 may affect normal lactation and
milk production, pup weights were recorded for litters
born to Six1-overexpressing dams. At 12 weeks of age,
female animals from both the 4922 and 6239 lines
began dox or vehicle-control treatment and MTB ani-
mals began dox treatment. All females were concur-
rently mated to wild-type males and were allowed to
undergo three rounds of pregnancy. Litter sizes were
normalized to eight pups and weights were taken each
day from lactation day 1 (L1) to L21 during one of the
three pregnancies, selected at random. No profound dif-
ferences in pup weights were identified between litters
b o r nt oT O S i x+ / -d o xa n dM T B+d o xd a m s ,s u g g e s t -
ing that TOSix dams lactate at a proficient level to meet
the nutritional needs of their pups (Fig. 5A). Interest-
ingly, we did note that a high percentage (approximately
80%) of 6239 TOSix +dox dams lost at least one of their
litters during the three rounds of pregnancy as com-
pared to 30-40% in MTB, 4922 line TOSix +/- dox, and
6239 line TOSix -dox animals (data not shown). How-
ever, this litter loss was inconsistent and did not appear
to follow a clear trend. Some dams lost their litter only
once during the three pregnancies, and in dams that
lost litters, the loss didn’t always occur in the same
sequence (i.e. first, second, or third). We thus cannot
attribute this finding to increased levels of Six1.
Although TOSix mothers capable of nursing did not
exhibit any phenotype suggestive of lactation failure,
we additionally analyzed mammary gland histology to
d e t e r m i n ea n yd i f f e r e n c eb e t w e e nt h eh i g h e s tS i x 1 -
expressing and control mammary glands during lacta-
tion. For these experiments, 6239 line TOSix and MTB
control virgin females were mated with wild-type males
and concurrently began dox treatment. Resulting litters
were normalized to eight pups, followed by sacrifice of
the mother at L2. Histology of the mammary glands
taken from TOSix (n = 3) and MTB (n = 3) dams
reveal similar histology, including expanded ducts filled
with milk (Fig. 5B). These results confirm the pup
weight experiment results and suggest that mammary
glands overexpressing Six1 are capable of fully differen-
tiating and functionally lactating. We also performed
this experiment using sucrose-treated animals and
found that they exhibited normal mammary histology
(data not shown).
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regresses following multiple pregnancies
Since Six1 is known to play a pro-proliferative and anti-
apoptotic role in numerous tissues [6-9], we hypothe-
sized that persistent Six1 expression may prevent proper
remodelling of the gland following pregnancy, thus con-
tributing to the hyperplasia that eventually arises in
these animals [30]. To test this hypothesis, TOSix
females from both the 4922 and 6239 lines, as well as
MTB controls began dox treatment at 12 weeks of age
and were concurrently mated. This experiment was per-
formed on the +dox TOSix group, and not the -dox
TOSix group, as both groups were previously shown to
equally exhibit hyperplasia after prolonged Six1 expres-
sion [30]. After the third pregnancy and 3 weeks of sub-
sequent nursing, pups were weaned, and mothers were
allowed to rest for four weeks to ensure complete invo-
lution before sacrifice. H&E stained sections reveal that
the epithelium in mammary glands expressing Six1,
taken from both the 4922 (n = 4) and 6239 (n = 2)
transgenic lines, properly regresses, exhibiting similar
histology to the glands taken from control MTB animals
(n = 7) (Fig. 6). Whole mount analysis also revealed that
TOSix mammary glands were fully regressed, similar to
MTB mammary glands (data not shown).
Discussion
Previous analysis demonstrated that Six1 expression is
low to absent in the normal adult human mammary
gland [11], and in agreement with this, its levels are very
low in normal human breast epithelial cell lines [26]. In
contrast, Six1 is overexpressed in both primary and
metastatic breast tumors, as well as in several human
breast cancer cell lines [11,26]. The molecular pathways
involved in carcinogenesis often represent aberrations of
normal processes that control embryogenesis [2]. Six1 is
highly expressed in cancers derived from tissues in
which it plays a fundamental role during embryogenesis
[28,32], and recent work demonstrates that overexpres-
sion of Six1 leads to an expansion of mammary stem/
Figure 4 Pregnancy occurs normally in TOSix animals. (A) Real-time quantitative PCR (qRT-PCR), using transgene specific primers and probe,
reveals that HASix1 is not expressed in the MTB control dox treated animals, but is expressed at low levels in the uninduced (-dox) mammary
glands, and at high levels in the induced (+dox) mammary glands. Animals were sacrificed at pregnancy day 18 (P18) after beginning treatment
with dox or sucrose vehicle-control at time of mating. Error bars denote mean ± sem. (B) H&E sections taken from MTB and TOSix mice. Animals
were sacrificed at pregnancy day 18 (P18) after beginning treatment with dox at time of mating. (C) H&E sections taken from TOSix mice
sacrificed at P18 after beginning treatment with sucrose-vehicle control at time of mating.
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Page 9 of 13progenitor cells [30]. These findings led us to reason
that Six1 may play an important role in normal mam-
mary gland development. Our results demonstrate that
Six1 expression is indeed differentially regulated in the
mammary epithelial compartment throughout mammary
gland development, consistent with the hypothesis that
Six1 plays a functional role in the development of the
gland. Expression of Six1 correlates with several
proliferative phases of mammary gland development,
including those that occur throughout the course of
ductal epithelial network development. Six1 transcript
levels decline during pregnancy and lactation, when the
mammary gland differentiates.
Studies in knockout mice demonstrate that Six1 is
required for the proper development of the kidney,
inner ear, thymus, nose, sensory neurons, muscle and
Figure 5 Six1-overexpressing dams lactate normally. (A) Average pup weight from TOSix and MTB litters, treated with dox or sucrose-vehicle
as noted. Litters were normalized to 8 pups and weights were taken daily from lactation day 1 (L1) to L21. Error bars denote mean ± sem. n =
average number of pups weighed (B) H&E stained sections taken from TOSix and MTB animals at L2. Animals began dox treatment at time of
mating.
Figure 6 Mammary glands overexpressing Six1 regress normally. H&E sections taken from TOSix and MTB animals after 6 months of dox
treatment (beginning at time of first mating) and after three rounds of pregnancy. Tissue was excised four weeks after weaning to ensure
complete involution.
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Page 10 of 13lacrimal and salivary glands [7,8,14-16,19]. Multiple
defects in Six1-deficient mice are associated with altera-
tions in the proliferation, death, and fate of progenitor
cells during embryogenesis [7,15,16,19]. In this study we
demonstrate that, although Six1 is dynamically
expressed in epithelial cells of the mammary gland dur-
ing embryogenesis, no alterations in cellular prolifera-
tion or death are observed in Six1
-/- mammary glands,
and these glands develop normally when transplanted
into Rag1
-/- host mice.
It is well accepted that members of homeobox gene
families exhibit functional redundancy [40,41], and such
redundancy could explain the lack of a phenotype in
Six1
-/- mammary glands. For example, redundancy has
been observed in the mammary glands of mutant mice
carrying deletions of paralogous homeobox genes Hoxa-
9, Hoxb-9,a n dHoxd-9 [41]. Single or double mutant
lines disrupted for Hoxa-9 and Hoxb-9 showed no mam-
mary gland phenotype, while animals simultaneously
lacking Hoxa-9, Hoxb-9,a n dHoxd-9 genes demon-
strated marked hypoplasia of the mammary gland after
parturition with gland morphology resembling that of a
midpregnant animal. Studies suggest that a compensa-
tory mechanism exists between Six family members.
Interestingly, these experiments have revealed that Six1
can compensate for Six4 in muscle development, as the
Six1/Six4 double knockout animals have more profound
phenotypes than the Six1 single or Six4 single knockout,
including failure of myogenic precursor cells to undergo
delamination from the dermomyotome and to migrate
to the limb bud, suggestive of a failure to induce an
epithelial to mesenchymal transition [23]. These studies
imply the existence of a unique redundant relationship
between Six1 and Six4. Interestingly, our results reveal
that both Six2 and Six4 are upregulated in the Six1
knockout mammary glands, suggesting that they may in
fact both compensate for loss of Six1 function. Recent
evidence demonstrates that Six2 regulates a stem cell
population in the kidney [38], while data from our
group has shown that Six1 may regulate the mammary
epithelial stem cell population [30]. Given the expres-
sion pattern of Six1 throughout normal mammary
development, Six1 may regulate expansion of stem/pro-
genitor cells in early development, a function that could
be compensated for by Six2. More studies need to be
performed to better understand the redundant mechan-
isms within the Six family.
Although knockout studies revealed that Six1 is not
required for mammary development, we postulated that
its downregulation during pregnancy, lactation, and
involution may be required for proper mammary gland
differentiation. Six1 has pro-proliferative and pro-survi-
val effects in a number of organ systems [6-9], and
therefore we hypothesized that Six1 expression out of
context during pregnancy, lactation, and involution, may
in fact prevent proper differentiation and, ultimately,
mammary function. Surprisingly, our results suggest
that inappropriate expression of Six1 does not inhibit
mammary gland differentiation during pregnancy, at
least by gross histological analysis. Additionally, pups
born to TOSix dams and control MTB dams thrive
equally, as measured by pup weight, suggesting that lac-
tation is also not influenced by the inappropriate expres-
sion of Six1. In confirmation of this finding, analysis of
mammary gland histology during lactation further
demonstrates that there is no significant defect in mam-
mary gland function.
Finally, since Six1 plays a pro-survival role during
development in other contexts [6-9], we hypothesized
that Six1 overexpression would thwart proper mammary
regression by preventing apoptosis and proper remodel-
ing of the mammary gland during involution, particu-
larly as we had previously shown that long term Six1
overexpression in multiparous mice leads to hyperplasia.
Again, our studies suggest that regression ultimately
occurs normally in young TOSix mice. It should be
noted that we examined only whether involution had
properly occurred 4 weeks after weaning. We did not
test whether Six1 overexpression may delay involution
by examining different time points throughout the early
stages of involution. Nonetheless, our studies suggest
that any effect of Six1 misexpression is overcome during
the course of involution. As alluded to above, recent
studies describing the role of Six1 in mammary tumor
initiation describe a hyperplasia phenotype that arises in
aged animals overexpressing Six1 [30]. Importantly, the
hyperplasia phenotype displays features of precocious
alveolar differentiation. While this suggests that Six1
may have some influence on pathways that control nor-
mal mammary differentiation, these phenotypes do not
arise until animals are aged, and are not present in the
younger animals used in this study. Six1-induced hyper-
plasia is thus most likely the result of an age-associated
alteration in another pathway that cooperates with Six1
overexpression. As the data presented here show that
regression of Six1-overexpressing mammary glands is
complete following lactation, we do not consider the
hyperplasia phenotype seen in aged animals as a “devel-
opmental” phenotype; rather, our data suggests that Six1
overexpression does not interfere with normal gland
function or development.
It is possible that inappropriate expression of Six1 in
later stages of development did not inhibit differentia-
tion, at least in part, due to the lack of availability of its
required cofactors Eya and Dach. Six1 is dependent on
the Eya and Dach transcriptional cofactors to activate
and/or repress transcription, as Six1 does not have an
intrinsic activation or repression domain [15]. When
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of pro-survival and pro-proliferative target genes are
repressed. However, if Eya is added to the complex,
Six1 switches from a repressor to an activator [15].
Thus, it is possible that the availability of cofactors in
the cell, as well as their stoichiometry with Six1, was
not conducive to stimulating the pro-proliferative and
anti-apoptotic functions of the protein, thereby remov-
ing the ability of aberrant Six1 expression to inhibit dif-
ferentiation. Interestingly, overexpression of Six1 over
long periods of time is sufficient to induce mammary
tumors [30], suggesting that the appropriate levels of
cofactors may be present for Six1 to properly activate
transcription in a tumorigenic context. However, it
remains to be determined whether this is indeed the
case. Additionally, mammary development is an evolu-
tionarily conserved process, and therefore multiple
mechanisms most likely exist to override signals that
would otherwise thwart proper development, such as
Six1 overexpression. Together with results from the
Six1 knockout mouse model, our data suggest that Six1
does not play a significant role in mammary gland
development in vivo.
Conclusions
In conclusion, we have shown that although Six1 is
dynamically expressed in the mammary epithelium dur-
ing mammary gland development, its expression is not
required for proper embryonic or postnatal develop-
ment, nor is its downregulation required for proper dif-
ferentiation. While unexpected, our findings have
significant implications for establishing whether Six1,
which is overexpressed in a large percentage of breast
cancers, is a reasonable chemotherapeutic target in a
clinical setting, especially for those women diagnosed
with breast cancer in their childbearing years. Of all the
women diagnosed with breast cancer each year in the
United States, 25% are diagnosed in their childbearing
years. These women may desire future opportunities for
pregnancy and lactation and therefore therapies that
avoid the destruction of normal mammary tissue may
prove advantageous in the clinic [42]. The fact that Six1
expression can induce mammary tumorigenesis and
metastasis in mouse models, that its loss does not con-
fer a mammary phenotype, and that it exhibits limited
expression in the majority of normal adult tissues [11],
makes it an exciting potential therapeutic target, as
therapies directed against Six1 may inhibit breast tumor-
igenesis on multiple fronts while conferring limited side
effects. Conditional knockout experiments in adult mice
will enable us to determine whether Six1 is required in
other adult tissues, and whether it truly could emerge as
a viable therapeutic target.
Additional file 1: Characterization of the Six1-deficient mice. (A) PCR
analyses of wild type (Six1
+/+), heterozygote (Six1
+/-), and knockout (Six1
-/-
) neonates. Tail DNA was isolated and PCR was performed using specific
primer pairs as described in the Methods section. (B) RT-PCR analyses of
mammary glands from Six1
+/+, Six1
+/- and Six1
-/- at day E18.5. Absence of
Six1 mRNA and expression of EGFP was confirmed in the Six1-deficient
mammary gland.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-213X-10-4-
S1.PDF]
Additional file 2: Loss of Six1 does not affect proliferation in the
mammary gland. Immunohistochemistry for BrdU was performed using
mammary glands taken from Six1-/- and wildtype mice. Positive and
negative cells were counted, both in ductal and alveolar structures, at d5
and d12 of pregnancy. Percent positive cells are represented.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-213X-10-4-
S2.PDF]
Acknowledgements
This work was funded by grants to H.L.F. from the National Cancer Institute
(2RO1-CA095277) and the American Cancer Society (RSG-07-183-01-DDC). E.
L.M. was funded by a predoctoral fellowship from the Department of
Defense Breast Cancer Research Program (W81XWH-06-1-0409). We would
like to thank Dr. Hidenori Ozaki for his work on the Six1 knockout mice. We
would like to thank members of the Ford, Anderson, Neville, and Sussel
laboratories for technical advice.
Author details
1Department of Obstetrics and Gynecology, University of Colorado Denver,
Anschutz Medical Campus, 12800 E. 19th Ave., Aurora, CO, 80045, USA.
2Program in Molecular Biology, University of Colorado Denver, Anschutz
Medical Campus, 12800 E. 19th Ave., Aurora, CO, 80045, USA.
3Departments
of Physiology and Biophysics, University of Colorado Denver, Anschutz
Medical Campus, 12800 E. 19th Ave., Aurora, CO, 80045, USA.
4Biochemistry
and Molecular Genetics, University of Colorado Denver, Anschutz Medical
Campus, 12800 E. 19th Ave., Aurora, CO, 80045, USA.
5Department of Oral
Diagnosis, State University of Campinas, School of Dentistry, Av. Limeira, 901
Caixa Postal 52, Piracicaba, SP, CEP 13414-903, Brazil.
6Division of Biology,
Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji,
Shimotsuke, Tochigi, 329-0498, Japan.
7Division of Endocrinology and
Metabolism, Department of Internal Medicine, Yale University School of
Medicine, PO Box 208020, New Haven, CT 06520-8020, USA.
Authors’ contributions
RDC carried out all transplant studies using the Six1 knockout mice,
performed RT-PCR and northern blot analysis, as well as PCR for genotyping,
completed immunostaining and cell proliferation and apoptosis analysis, and
participated in drafting the manuscript. ELM performed all studies using the
TOSix bi-transgenic mouse model, qRT-PCR for Six family members in Six1
knockout mammary glands, and participated in drafting the manuscript. VB
assisted in transplant studies. KK provided the Six1 knockout mice. JLM
assisted with the analysis of the mammary glands upon aberrant Six1
overexpression, and JJW assisted with analysis of embryonic mammary
glands. HLF conceived the study, participated in its design and coordination,
funded the study, and helped to draft the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 August 2009
Accepted: 14 January 2010 Published: 14 January 2010
References
1. Pearson JC, Lemons D, McGinnis W: Modulating Hox gene functions
during animal body patterning. Nat Rev Genet 2005, 6:893-904.
Coletta et al. BMC Developmental Biology 2010, 10:4
http://www.biomedcentral.com/1471-213X/10/4
Page 12 of 132. Abate-Shen C: Deregulated homeobox gene expression in cancer: cause
or consequence?. Nat Rev Cancer 2002, 2:777-785.
3. Samuel S, Naora H: Homeobox gene expression in cancer: insights from
developmental regulation and deregulation. Eur J Cancer 2005,
41:2428-2437.
4. Argiropoulos B, Humphries RK: Hox genes in hematopoiesis and
leukemogenesis. Oncogene 2007, 26:6766-6776.
5. Christensen KL, Patrick AN, McCoy EL, Ford HL: The six family of
homeobox genes in development and cancer. Adv Cancer Res 2008,
101:93-126.
6. Li X, Perissi V, Liu F, Rose DW, Rosenfeld MG: Tissue-specific regulation of
retinal and pituitary precursor cell proliferation. Science 2002,
297:1180-1183.
7. Xu PX, Zheng W, Huang L, Maire P, Laclef C, Silvius D: Six1 is required for
the early organogenesis of mammalian kidney. Development 2003,
130:3085-3094.
8. Zheng W, Huang L, Wei ZB, Silvius D, Tang B, Xu PX: The role of Six1 in
mammalian auditory system development. Development 2003,
130:3989-4000.
9. Zuber ME, Perron M, Philpott A, Bang A, Harris WA: Giant eyes in Xenopus
laevis by overexpression of XOptx2. Cell 1999, 98:341-352.
10. Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A,
Ford HL: Six1 overexpression in ovarian carcinoma causes resistance to
TRAIL-mediated apoptosis and is associated with poor survival. Cancer
Res 2007, 67:3036-3042.
11. Ford HL, Kabingu EN, Bump EA, Mutter GL, Pardee AB: Abrogation of the
G2 cell cycle checkpoint associated with overexpression of HSIX1: a
possible mechanism of breast carcinogenesis. Proc Natl Acad Sci USA
1998, 95:12608-12613.
12. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G: Expression
profiling identifies the cytoskeletal organizer ezrin and the
developmental homeoprotein Six-1 as key metastatic regulators. Nat
Med 2004, 10:175-181.
13. Coletta RD, Christensen KL, Micalizzi DS, Jedlicka P, Varella-Garcia M,
Ford HL: Six1 overexpression in mammary cells induces genomic
instability and is sufficient for malignant transformation. Cancer Res 2008,
68:2204-2213.
14. Laclef C, Souil E, Demignon J, Maire P: Thymus, kidney and craniofacial
abnormalities in Six 1 deficient mice. Mech Dev 2003, 120:669-679.
15. Li X, Oghi KA, Zhang J, Krones A, Bush KT, Glass CK, Nigam SK,
Aggarwal AK, Maas R, Rose DW, Rosenfeld MG: Eya protein phosphatase
activity regulates Six1-Dach-Eya transcriptional effects in mammalian
organogenesis. Nature 2003, 426:247-254.
16. Ozaki H, Nakamura K, Funahashi J, Ikeda K, Yamada G, Tokano H,
Okamura HO, Kitamura K, Muto S, Kotaki H, et al: Six1 controls patterning
of the mouse otic vesicle. Development 2004, 131:551-562.
17. Laclef C, Hamard G, Demignon J, Souil E, Houbron C, Maire P: Altered
myogenesis in Six1-deficient mice. Development 2003, 130:2239-2252.
18. Konishi Y, Ikeda K, Iwakura Y, Kawakami K: Six1 and Six4 promote survival
of sensory neurons during early trigeminal gangliogenesis. Brain Res
2006, 1116:93-102.
19. Zou D, Silvius D, Fritzsch B, Xu PX: Eya1 and Six1 are essential for early
steps of sensory neurogenesis in mammalian cranial placodes.
Development 2004, 131:5561-5572.
20. Ikeda K, Ookawara S, Sato S, Ando Z, Kageyama R, Kawakami K: Six1 is
essential for early neurogenesis in the development of olfactory
epithelium. Dev Biol 2007, 311:53-68.
21. Oliver G, Wehr R, Jenkins NA, Copeland NG, Cheyette BN, Hartenstein V,
Zipursky SL, Gruss P: Homeobox genes and connective tissue patterning.
Development 1995, 121:693-705.
22. McCoy EL, Kawakami K, Ford HL, Coletta R: Expression of Six1 homeobox
gene during development of the mouse submandibular salivary gland.
Oral Dis 2009, 15(6):407-413.
23. Grifone R, Demignon J, Houbron C, Souil E, Niro C, Seller MJ, Hamard G,
Maire P: Six1 and Six4 homeoproteins are required for Pax3 and Mrf
expression during myogenesis in the mouse embryo. Development 2005,
132:2235-2249.
24. Wan F, Miao X, Quraishi I, Kennedy V, Creek KE, Pirisi L: Gene expression
changes during HPV-mediated carcinogenesis: a comparison between
an in vitro cell model and cervical cancer. Int J Cancer 2008, 123:32-40.
25. Ng KT, Man K, Sun CK, Lee TK, Poon RT, Lo CM, Fan ST: Clinicopathological
significance of homeoprotein Six1 in hepatocellular carcinoma. Br J
Cancer 2006, 95:1050-1055.
26. Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D,
Huang L, Wolf DM, Muller-Tidow C, Golub TR, Kawakami K, Ford HL: The
Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin
A1. Proc Natl Acad Sci USA 2004, 101:6478-6483.
27. Reichenberger KJ, Coletta RD, Schulte AP, Varella-Garcia M, Ford HL: Gene
amplification is a mechanism of Six1 overexpression in breast cancer.
Cancer Res 2005, 65:2668-2675.
28. Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC,
Pavan WJ, Trent JM, Meltzer PS: cDNA microarrays detect activation of a
myogenic transcription program by the PAX3-FKHR fusion oncogene.
Proc Natl Acad Sci USA 1999, 96:13264-13269.
29. Li CM, Guo M, Borczuk A, Powell CA, Wei M, Thaker HM, Friedman R,
Klein U, Tycko B: Gene expression in Wilms’ tumor mimics the earliest
committed stage in the metanephric mesenchymal-epithelial transition.
Am J Pathol 2002, 160:2181-2190.
30. McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA,
Welm AL, Ford HL: Six1 expands the mouse mammary epithelial stem/
progenitor cell pool and induces mammary tumors that undergo
epithelial-mesenchymal transition. J Clin Invest 2009, 119:2663-2677.
31. Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Baron AE, Harrell JC,
Horwitz KB, Billheimer D, Heichman KA, Welm AL, et al: The Six1
homeoprotein induces human mammary carcinoma cells to undergo
epithelial-mesenchymal transition and metastasis in mice through
increasing TGF-beta signaling. J Clin Invest 2009, 119:2678-2690.
32. Li P, Yu X, Ge K, Melamed J, Roeder RG, Wang Z: Heterogeneous
expression and functions of androgen receptor co-factors in primary
prostate cancer. Am J Pathol 2002, 161:1467-1474.
33. D’Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE,
Cox JD, Ha SI, Belka GK, Golant A, et al: c-MYC induces mammary
tumorigenesis by means of a preferred pathway involving spontaneous
Kras2 mutations. Nat Med 2001, 7:235-239.
34. Lewis MT, Ross S, Strickland PA, Sugnet CW, Jimenez E, Scott MP,
Daniel CW: Defects in mouse mammary gland development caused by
conditional haploinsufficiency of Patched-1. Development 1999,
126:5181-5193.
35. Dunbar ME, Wysolmerski JJ: Mammary ductal and alveolar development:
lesson learned from genetically manipulated mice. Microsc Res Tech 2001,
52:163-170.
36. McManaman JL, Reyland ME, Thrower EC: Secretion and fluid transport
mechanisms in the mammary gland: comparisons with the exocrine
pancreas and the salivary gland. J Mammary Gland Biol Neoplasia 2006,
11:249-268.
37. Ozaki H, Watanabe Y, Takahashi K, Kitamura K, Tanaka A, Urase K, Momoi T,
Sudo K, Sakagami J, Asano M, et al: Six4, a putative myogenin gene
regulator, is not essential for mouse embryonal development. Mol Cell
Biol 2001, 21:3343-3350.
38. Kobayashi A, Valerius MT, Mugford JW, Carroll TJ, Self M, Oliver G,
McMahon AP: Six2 defines and regulates a multipotent self-renewing
nephron progenitor population throughout mammalian kidney
development. Cell Stem Cell 2008, 3:169-181.
39. Gunther EJ, Belka GK, Wertheim GB, Wang J, Hartman JL, Boxer RB,
Chodosh LA: A novel doxycycline-inducible system for the transgenic
analysis of mammary gland biology. FASEB J 2002, 16:283-292.
40. Satokata I, Ma L, Ohshima H, Bei M, Woo I, Nishizawa K, Maeda T, Takano Y,
Uchiyama M, Heaney S, et al: Msx2 deficiency in mice causes pleiotropic
defects in bone growth and ectodermal organ formation. Nat Genet
2000, 24:391-395.
41. Chen F, Capecchi MR: Paralogous mouse Hox genes, Hoxa9, Hoxb9, and
Hoxd9, function together to control development of the mammary
gland in response to pregnancy. Proc Natl Acad Sci USA 1999, 96:541-546.
42. Camune B, Gabzdyl E: Breast-feeding after breast cancer in childbearing
women. J Perinat Neonatal Nurs 2007, 21:225-233.
doi:10.1186/1471-213X-10-4
Cite this article as: Coletta et al.: Characterization of the Six1 homeobox
gene in normal mammary gland morphogenesis. BMC Developmental
Biology 2010 10:4.
Coletta et al. BMC Developmental Biology 2010, 10:4
http://www.biomedcentral.com/1471-213X/10/4
Page 13 of 13